Russia’s Sputnik V vaccine is 91.6 percent effective against symptomatic COVID-19, according to an analysis published in The Lancet on Tuesday that independent experts said allayed transparency concerns over the jab, which Moscow is already rolling out.
NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr— The Lancet (@TheLancet) February 2, 2021
The preliminary findings show that the two-dose Sputnik V “has shown high efficacy” and was well tolerated for participants over 18 in final-stage clinical trials, said co-lead author Inna Dolzhikova of Russia’s Gamaleya National Research center for Epidemiology and Microbiology.